Generali Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Generali Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.94M	Sell	17,425 -8,125	-32%	-$1.21M	0.05%	250
2026 Q1	$3.37M	Buy	25,550 +2,847	+13%	+$378K	0.07%	228
2025 Q4	$3.22M	Sell	22,703 -3,657	-14%	-$530K	0.07%	237
2025 Q3	$3.7M	Sell	26,360 -2,705	-9%	-$367K	0.08%	215
2025 Q2	$3.65M	Buy	29,065 +21,736	+297%	+$2.49M	0.08%	218
2025 Q1	$811K	Sell	7,329 -16,276	-69%	-$2.06M	0.02%	403
2024 Q4	$3.22M	Buy	+23,605	New	+$2.92M	0.08%	226

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Generali Asset Management's NBIX Position: Q2 2026 in Review

Generali Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 32% in Q2 2026, selling an estimated $1.21M and leaving 17,425 shares worth $2.94M. The position accounts for 0.05% of the portfolio, ranked #250.

Generali Asset Management first reported a position in NBIX in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.7M in Q3 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Generali Asset Management held 17,425 shares of Neurocrine Biosciences worth $2.94M as of Q2 2026.
Generali Asset Management sold 8,125 Neurocrine Biosciences shares in Q2 2026, an estimated $1.21M.
Neurocrine Biosciences made up 0.05% of Generali Asset Management's portfolio in Q2 2026, its #250 holding.
Generali Asset Management first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 7 quarters since.
Generali Asset Management's Neurocrine Biosciences position peaked at $3.7M in Q3 2025.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Generali Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.